We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Smith & Nephew Plc | LSE:SN. | London | Ordinary Share | GB0009223206 | ORD USD0.20 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 6.20 | 0.62% | 1,004.00 | 1,003.50 | 1,004.50 | 1,007.50 | 999.20 | 1,001.00 | 375,116 | 13:44:58 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Ortho,prosth,surg Appl,suply | 5.55B | 263M | 0.3011 | 33.36 | 8.77B |
From May 2021 to May 2024
TIDMSN.
RNS Number : 4933Z
Smith & Nephew Plc
21 May 2021
SMITH & NEPHEW PLC
21 May 2021
NOTIFICATION AND PUBLIC DISCLOSURE IN ACCORDANCE WITH THE REQUIREMENTS OF THE EU MARKET ABUSE REGULATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES ("PDMR") AND PERSONS CLOSELY ASSOCIATED WITH THEM.
On 21 May 2021 the following awards of US$0.20 ordinary shares (the "Shares") in Smith & Nephew plc (the "Company") were granted under the Smith & Nephew Global Share Plan 2020. The awards have been made in London and are based on the closing Share price on the London Stock Exchange on 20 May 2021 of GBP15.495.
1. PERFORMANCE SHARE PROGRAMME 2021 AWARDS GRANTED UNDER THE SMITH & NEPHEW GLOBAL SHARE PLAN 2020
The Remuneration Committee has approved performance conditions attached to the vesting of these awards, which are detailed below. These awards will vest on 21 May 2024 for the Executive Directors and 9 March 2024 for the other participants, subject to the achievement of the performance conditions which are measured over the period 1 January 2021 to 31 December 2023 as set out below.
The number of shares subject to the above awards are shown at target vesting. Should maximum vesting be achieved, participants will receive 2x the number of shares shown below. Participants will receive an additional number of shares equivalent to the amount of dividend payable per vested share during the relevant performance period.
The following relates to all individuals included in this section:
Hot Features
Premium
Reason for the notification
Initial notification Initial notification
/Amendment
-------------------------------------------
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
Name Smith & Nephew plc
-------------------------------------------
LEI 213800ZTMDN8S67S1H61
-------------------------------------------
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
Description of the Smith & Nephew plc Ordinary Shares of USD
financial instrument, 0.20 each
type of instrument
-------------------------------------------
Identification code ISIN: GB0009223206
-------------------------------------------
Nature of the transaction Performance Share Awards granted at target
on 21 May 2021 under the Smith & Nephew
Global Share Plan 2020.
-------------------------------------------
Date of Transaction 2021 - 05 -- 21
-------------------------------------------
Place of Transaction London Stock Exchange (XLON)
-------------------------------------------
Director /
Name (Position) PDMR Price (GBP) Volume Aggregated information
Bradley Cannon
(President Sports
Medicine & ENT) PDMR 15.495 57,367 N/A Single Transaction
------------ ------------ ------- -----------------------
Peter Coenen
(President EMEA
Region) PDMR 15.495 31,627 N/A Single Transaction
------------ ------------ ------- -----------------------
Phil Cowdy
(Chief Business
Development &
Corporate Affairs
Officer) PDMR 15.495 25,605 N/A Single Transaction
------------ ------------ ------- -----------------------
Roland Diggelmann
(Chief Executive Executive
Officer) Director 15.495 96,174 N/A Single Transaction
------------ ------------ ------- -----------------------
Myra Eskes
(President APAC
Region) PDMR 15.495 32,625 N/A Single Transaction
------------ ------------ ------- -----------------------
Simon Fraser
(President Advanced
Wound Management) PDMR 15.495 49,153 N/A Single Transaction
------------ ------------ ------- -----------------------
Melissa Guerdan
(Chief Quality
& Regulatory
Affairs Officer) PDMR 15.495 30,423 N/A Single Transaction
------------ ------------ ------- -----------------------
Skip Kiil
(President Orthopaedics) PDMR 15.495 70,367 N/A Single Transaction
------------ ------------ ------- -----------------------
Elga Lohler
(Chief HR Officer) PDMR 15.495 32,622 N/A Single Transaction
------------ ------------ ------- -----------------------
Anne-Françoise
Nesmes
(Chief Financial Executive
Officer) Director 15.495 51,468 N/A Single Transaction
------------ ------------ ------- -----------------------
Catheryn O'Rourke
(Chief Legal
& Compliance
Officer) PDMR 15.495 34,098 N/A Single Transaction
------------ ------------ ------- -----------------------
Vasant Padmanabhan
(President Research
& Development) PDMR 15.495 31,967 N/A Single Transaction
------------ ------------ ------- -----------------------
Susan Swabey
(Company Secretary) PDMR 15.495 5,484 N/A Single Transaction
------------ ------------ ------- -----------------------
As explained on page 119 of the 2020 Annual Report the performance conditions applying to these awards have been determined by the Remuneration Committee having now had more time to understand how COVID-19 might impact upon our business between 2021 and 2023.
The awards made to the Executive Directors are subject to four equally weighted performance measures: Total Shareholder Return (TSR), Return on Invested Capital (ROIC), Global Revenue Growth and Cumulative Free Cash Flow. Page 119 of the 2020 Annual Report explains how TSR will be measured and defines the calculation of ROIC.
The awards subject to TSR will vest as follows. The two equally weighted peer groups are defined on page 119 of the 2020 Annual Report.
Award vesting as % of salary at date of
grant
Sector based peer group FTSE100 peer group
------------------------ -------------------
Below the index Nil Nil
------------------------ -------------------
Equaling the index 8.6% 8.6%
------------------------ -------------------
8% above the index 34.4% 34.4%
------------------------ -------------------
Awards will vest on a straight-line basis between these points. The maximum has been set significantly above target reflecting the maximum opportunity for outperformance.
The awards subject to ROIC will vest as follows:
Return on Invested Capital Award vesting as a % of salary
Year ended 31 December 2023
Below 9.8% Nil
-------------------------------
9.8% 17.2%
-------------------------------
11.8% 34.4%
-------------------------------
13.8% 68.8%
-------------------------------
Awards will vest on a straight-line basis between these points.
The awards subject to Revenue Growth will vest as follows:
Three years ended 31 December Award vesting as a % of salary
2023
Below Threshold Nil
-------------------------------
Threshold (-8% of target) 17.2%
-------------------------------
Target - set by reference to
our expectations 34.4%
-------------------------------
Maximum or above (+8% of target) 68.8%
-------------------------------
Awards will vest on a straight-line basis between these points.
Revenue Growth targets for the three years ended 31 December 2023 for these awards, even though now determined, will not be disclosed until the 2023 Annual Report, when the Remuneration Committee will discuss performance against the target. It is not possible to disclose precise targets at the time of grant to avoid giving commercially sensitive information to our competitors concerning our growth plans.
The awards subject to Cumulative Free Cash Flow will vest as follows:
Cumulative free cash flow Award vesting as % of salary
Three years ended 31 December
2023
Below $1,370m Nil
-----------------------------
$1,370m 17.2%
-----------------------------
$1,712m 34.4%
-----------------------------
$2,054m 68.8%
-----------------------------
Awards will vest on a straight-line basis between these points.
Susan Swabey
Company Secretary
Smith & Nephew plc
Tel: +44 (0)1923 477410
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHFLFFEERILFIL
(END) Dow Jones Newswires
May 21, 2021 11:30 ET (15:30 GMT)
1 Year Smith & Nephew Chart |
1 Month Smith & Nephew Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
